Eli Lilly and Company

Timothy Wayne Noblitt

Derrick Ryan Witcher

Ling Liu

Radmila Micanovic

John Edward Hale

Gerald W Becker

Sheng-Hung Rainbow Tschang

Radhakrishnan Rathnachalam

Fredric Jay Cohen

Patricia Ann Gonzalez-DeWhitt

Christy Michelle Newton

Victor John Wroblewski

Josef Georg Heuer

The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antagonist, LP82 polynucleotide, LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

Use of LP82 to treat hematopoietic disorders

Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.

Flint polypeptide analogs

Growing community of inventors

Fishers, IN, United States of America

Timothy Wayne Noblitt